<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:g="http://xbrl.dcca.dk/sob" xmlns:b="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:h="http://xbrl.dcca.dk/mrv" xmlns:f="http://xbrl.dcca.dk/arr" xmlns:d="http://xbrl.dcca.dk/cmn" xmlns:e="http://xbrl.dcca.dk/fsa" xmlns:c="http://xbrl.dcca.dk/gsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd"><link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd"/><c:InformationOnTypeOfSubmittedReport contextRef="c1">Årsrapport</c:InformationOnTypeOfSubmittedReport><c:IdentificationNumberCvrOfSubmittingEnterprise contextRef="c1">34209936</c:IdentificationNumberCvrOfSubmittingEnterprise><c:NameOfSubmittingEnterprise contextRef="c1">Grant Thornton, Godkendt Revisionspartnerselskab</c:NameOfSubmittingEnterprise><c:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="c1">Stockholmsgade, 45</c:AddressOfSubmittingEnterpriseStreetAndNumber><c:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="c1">2100, København Ø</c:AddressOfSubmittingEnterprisePostcodeAndTown><c:PrecedingReportingPeriodStartDate contextRef="c1">2022-01-01</c:PrecedingReportingPeriodStartDate><c:PredingReportingPeriodEndDate contextRef="c1">2022-12-31</c:PredingReportingPeriodEndDate><c:ReportingPeriodStartDate contextRef="c1">2023-01-01</c:ReportingPeriodStartDate><c:ReportingPeriodEndDate contextRef="c1">2023-12-31</c:ReportingPeriodEndDate><c:IdentificationNumberCvrOfReportingEntity contextRef="c1">26527651</c:IdentificationNumberCvrOfReportingEntity><c:NameOfReportingEntity contextRef="c1">PharmAdvice ApS</c:NameOfReportingEntity><c:AddressOfReportingEntityStreetName contextRef="c1">Generatorvej 8 C, 1.</c:AddressOfReportingEntityStreetName><c:AddressOfReportingEntityStreetBuildingIdentifier contextRef="c1">tv.</c:AddressOfReportingEntityStreetBuildingIdentifier><c:AddressOfReportingEntityPostCodeIdentifier contextRef="c1">2860</c:AddressOfReportingEntityPostCodeIdentifier><c:AddressOfReportingEntityDistrictName contextRef="c1">Søborg</c:AddressOfReportingEntityDistrictName><d:NameOfAuditFirm contextRef="c37">Grant Thornton, Godkendt Revisionspartnerselskab</d:NameOfAuditFirm><d:IdentificationNumberCvrOfAuditFirm contextRef="c37">34209936</d:IdentificationNumberCvrOfAuditFirm><d:NameAndSurnameOfAuditor contextRef="c37">Anders Holmgaard Christiansen</d:NameAndSurnameOfAuditor><d:DescriptionOfAuditor contextRef="c37">statsautoriseret revisor</d:DescriptionOfAuditor><d:IdentificationNumberOfAuditor contextRef="c37">mne34111</d:IdentificationNumberOfAuditor><c:AddressOfAuditorStreetName contextRef="c37">Stockholmsgade</c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c37">45</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c37">2100</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorDistrictName contextRef="c37">København Ø</c:AddressOfAuditorDistrictName><c:AddressOfAuditorCountry contextRef="c37">Danmark</c:AddressOfAuditorCountry><c:TelephoneNumberOfAuditor contextRef="c37">+45 33 110 220</c:TelephoneNumberOfAuditor><c:EmailOfAuditor contextRef="c1">info@dk.gt.com</c:EmailOfAuditor><c:DateOfGeneralMeeting contextRef="c1">2024-05-16</c:DateOfGeneralMeeting><c:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="c1">Susanne Ølsgaard Felumb</c:NameAndSurnameOfChairmanOfGeneralMeeting><e:ClassOfReportingEntity contextRef="c1">Regnskabsklasse B</e:ClassOfReportingEntity><d:TypeOfAuditorAssistance contextRef="c1">Andre erklæringer uden sikkerhed</d:TypeOfAuditorAssistance><c:ToolForPreparingTheXBRLInstanceDocument contextRef="c1">CaseWare fra Revisorgruppen Danmark</c:ToolForPreparingTheXBRLInstanceDocument><f:AddresseeOfAuditorsReportOnOtherReport contextRef="c1">anpartshaveren</f:AddresseeOfAuditorsReportOnOtherReport><f:SignatureOfAuditorsPlace contextRef="c1">København</f:SignatureOfAuditorsPlace><f:SignatureOfAuditorsDate contextRef="c1">2024-05-16</f:SignatureOfAuditorsDate><g:PlaceOfSignatureOfStatement contextRef="c1">Søborg</g:PlaceOfSignatureOfStatement><g:DateOfApprovalOfAnnualReport contextRef="c1">2024-05-16</g:DateOfApprovalOfAnnualReport><e:GrossProfitLoss contextRef="c1" unitRef="u5" decimals="0">5940070</e:GrossProfitLoss><e:GrossProfitLoss contextRef="c2" unitRef="u5" decimals="0">5311830</e:GrossProfitLoss><e:EmployeeBenefitsExpense contextRef="c1" unitRef="u5" decimals="0">5132413</e:EmployeeBenefitsExpense><e:EmployeeBenefitsExpense contextRef="c2" unitRef="u5" decimals="0">4365412</e:EmployeeBenefitsExpense><e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c1" unitRef="u5" decimals="0">12272</e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c2" unitRef="u5" decimals="0">15123</e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c1" unitRef="u5" decimals="0">795385</e:ProfitLossFromOrdinaryOperatingActivities><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c2" unitRef="u5" decimals="0">931295</e:ProfitLossFromOrdinaryOperatingActivities><e:OtherFinanceIncome contextRef="c1" unitRef="u5" decimals="0">203</e:OtherFinanceIncome><e:OtherFinanceIncome contextRef="c2" unitRef="u5" decimals="0">0</e:OtherFinanceIncome><e:OtherFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">15333</e:OtherFinanceExpenses><e:OtherFinanceExpenses contextRef="c2" unitRef="u5" decimals="0">10427</e:OtherFinanceExpenses><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c1" unitRef="u5" decimals="0">780255</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c2" unitRef="u5" decimals="0">920868</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:TaxExpense contextRef="c1" unitRef="u5" decimals="0">171730</e:TaxExpense><e:TaxExpense contextRef="c2" unitRef="u5" decimals="0">203866</e:TaxExpense><e:ProfitLoss contextRef="c1" unitRef="u5" decimals="0">608525</e:ProfitLoss><e:ProfitLoss contextRef="c2" unitRef="u5" decimals="0">717002</e:ProfitLoss><e:ProposedDividendRecognisedInEquity contextRef="c4" unitRef="u5" decimals="0">600000</e:ProposedDividendRecognisedInEquity><e:ProposedDividendRecognisedInEquity contextRef="c3" unitRef="u5" decimals="0">700000</e:ProposedDividendRecognisedInEquity><e:TransferredToFromRetainedEarnings contextRef="c1" unitRef="u5" decimals="0">8525</e:TransferredToFromRetainedEarnings><e:TransferredToFromRetainedEarnings contextRef="c2" unitRef="u5" decimals="0">17002</e:TransferredToFromRetainedEarnings><e:FixturesFittingsToolsAndEquipment contextRef="c4" unitRef="u5" decimals="0">343</e:FixturesFittingsToolsAndEquipment><e:FixturesFittingsToolsAndEquipment contextRef="c3" unitRef="u5" decimals="0">12615</e:FixturesFittingsToolsAndEquipment><e:PropertyPlantAndEquipment contextRef="c4" unitRef="u5" decimals="0">343</e:PropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c3" unitRef="u5" decimals="0">12615</e:PropertyPlantAndEquipment><e:DepositsLongtermInvestmentsAndReceivables contextRef="c4" unitRef="u5" decimals="0">153001</e:DepositsLongtermInvestmentsAndReceivables><e:DepositsLongtermInvestmentsAndReceivables contextRef="c3" unitRef="u5" decimals="0">137701</e:DepositsLongtermInvestmentsAndReceivables><e:LongtermInvestmentsAndReceivables contextRef="c4" unitRef="u5" decimals="0">153001</e:LongtermInvestmentsAndReceivables><e:LongtermInvestmentsAndReceivables contextRef="c3" unitRef="u5" decimals="0">137701</e:LongtermInvestmentsAndReceivables><e:NoncurrentAssets contextRef="c4" unitRef="u5" decimals="0">153344</e:NoncurrentAssets><e:NoncurrentAssets contextRef="c3" unitRef="u5" decimals="0">150316</e:NoncurrentAssets><e:ShorttermTradeReceivables contextRef="c4" unitRef="u5" decimals="0">1406593</e:ShorttermTradeReceivables><e:ShorttermTradeReceivables contextRef="c3" unitRef="u5" decimals="0">1455535</e:ShorttermTradeReceivables><e:CurrentDeferredTaxAssets contextRef="c4" unitRef="u5" decimals="0">6630</e:CurrentDeferredTaxAssets><e:CurrentDeferredTaxAssets contextRef="c3" unitRef="u5" decimals="0">6166</e:CurrentDeferredTaxAssets><e:OtherShorttermReceivables contextRef="c4" unitRef="u5" decimals="0">0</e:OtherShorttermReceivables><e:OtherShorttermReceivables contextRef="c3" unitRef="u5" decimals="0">31842</e:OtherShorttermReceivables><e:DeferredIncomeAssets contextRef="c4" unitRef="u5" decimals="0">0</e:DeferredIncomeAssets><e:DeferredIncomeAssets contextRef="c3" unitRef="u5" decimals="0">18731</e:DeferredIncomeAssets><e:ShorttermReceivables contextRef="c4" unitRef="u5" decimals="0">1413223</e:ShorttermReceivables><e:ShorttermReceivables contextRef="c3" unitRef="u5" decimals="0">1512274</e:ShorttermReceivables><e:CashAndCashEquivalents contextRef="c4" unitRef="u5" decimals="0">675196</e:CashAndCashEquivalents><e:CashAndCashEquivalents contextRef="c3" unitRef="u5" decimals="0">622181</e:CashAndCashEquivalents><e:CurrentAssets contextRef="c4" unitRef="u5" decimals="0">2088419</e:CurrentAssets><e:CurrentAssets contextRef="c3" unitRef="u5" decimals="0">2134455</e:CurrentAssets><e:Assets contextRef="c4" unitRef="u5" decimals="0">2241763</e:Assets><e:Assets contextRef="c3" unitRef="u5" decimals="0">2284771</e:Assets><e:RecognisedButNotOwnedAssets contextRef="c1" unitRef="u5" decimals="0">0</e:RecognisedButNotOwnedAssets><e:ContributedCapital contextRef="c4" unitRef="u5" decimals="0">125000</e:ContributedCapital><e:ContributedCapital contextRef="c3" unitRef="u5" decimals="0">125000</e:ContributedCapital><e:RetainedEarnings contextRef="c4" unitRef="u5" decimals="0">714821</e:RetainedEarnings><e:RetainedEarnings contextRef="c3" unitRef="u5" decimals="0">706298</e:RetainedEarnings><e:ProposedDividendRecognisedInEquity contextRef="c4" unitRef="u5" decimals="0">600000</e:ProposedDividendRecognisedInEquity><e:ProposedDividendRecognisedInEquity contextRef="c3" unitRef="u5" decimals="0">700000</e:ProposedDividendRecognisedInEquity><e:Equity contextRef="c4" unitRef="u5" decimals="0">1439821</e:Equity><e:Equity contextRef="c3" unitRef="u5" decimals="0">1531298</e:Equity><e:LongtermPayablesToGroupEnterprises contextRef="c4" unitRef="u5" decimals="0">17256</e:LongtermPayablesToGroupEnterprises><e:LongtermPayablesToGroupEnterprises contextRef="c3" unitRef="u5" decimals="0">0</e:LongtermPayablesToGroupEnterprises><e:LongtermLiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">17256</e:LongtermLiabilitiesOtherThanProvisions><e:LongtermLiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">0</e:LongtermLiabilitiesOtherThanProvisions><e:ShorttermTradePayables contextRef="c4" unitRef="u5" decimals="0">165327</e:ShorttermTradePayables><e:ShorttermTradePayables contextRef="c3" unitRef="u5" decimals="0">221816</e:ShorttermTradePayables><e:ShorttermTaxPayablesToGroupEnterprises contextRef="c4" unitRef="u5" decimals="0">172194</e:ShorttermTaxPayablesToGroupEnterprises><e:ShorttermTaxPayablesToGroupEnterprises contextRef="c3" unitRef="u5" decimals="0">287283</e:ShorttermTaxPayablesToGroupEnterprises><e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="c4" unitRef="u5" decimals="0">447165</e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="c3" unitRef="u5" decimals="0">244374</e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">784686</e:ShorttermLiabilitiesOtherThanProvisions><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">753473</e:ShorttermLiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">801942</e:LiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">753473</e:LiabilitiesOtherThanProvisions><e:LiabilitiesAndEquity contextRef="c4" unitRef="u5" decimals="0">2241763</e:LiabilitiesAndEquity><e:LiabilitiesAndEquity contextRef="c3" unitRef="u5" decimals="0">2284771</e:LiabilitiesAndEquity><e:WagesAndSalaries contextRef="c1" unitRef="u5" decimals="0">4276833</e:WagesAndSalaries><e:WagesAndSalaries contextRef="c2" unitRef="u5" decimals="0">3693122</e:WagesAndSalaries><e:PostemploymentBenefitExpense contextRef="c1" unitRef="u5" decimals="0">807774</e:PostemploymentBenefitExpense><e:PostemploymentBenefitExpense contextRef="c2" unitRef="u5" decimals="0">624755</e:PostemploymentBenefitExpense><e:SocialSecurityContributions contextRef="c1" unitRef="u5" decimals="0">20923</e:SocialSecurityContributions><e:SocialSecurityContributions contextRef="c2" unitRef="u5" decimals="0">19693</e:SocialSecurityContributions><e:OtherEmployeeExpense contextRef="c1" unitRef="u5" decimals="0">26883</e:OtherEmployeeExpense><e:OtherEmployeeExpense contextRef="c2" unitRef="u5" decimals="0">27842</e:OtherEmployeeExpense><e:EmployeeBenefitsExpense contextRef="c1" unitRef="u5" decimals="0">5132413</e:EmployeeBenefitsExpense><e:EmployeeBenefitsExpense contextRef="c2" unitRef="u5" decimals="0">4365412</e:EmployeeBenefitsExpense><e:AverageNumberOfEmployees contextRef="c1" unitRef="u7" decimals="INF">6</e:AverageNumberOfEmployees><e:AverageNumberOfEmployees contextRef="c2" unitRef="u7" decimals="INF">6</e:AverageNumberOfEmployees><e:Equity contextRef="c119" unitRef="u5" decimals="0">125000</e:Equity><e:Equity contextRef="c478" unitRef="u5" decimals="0">125000</e:Equity><e:Equity contextRef="c121" unitRef="u5" decimals="0">125000</e:Equity><e:Equity contextRef="c480" unitRef="u5" decimals="0">125000</e:Equity><e:Equity contextRef="c137" unitRef="u5" decimals="0">706296</e:Equity><e:Equity contextRef="c498" unitRef="u5" decimals="0">689296</e:Equity><e:ProfitLoss contextRef="c138" unitRef="u5" decimals="0">8525</e:ProfitLoss><e:ProfitLoss contextRef="c499" unitRef="u5" decimals="0">492002</e:ProfitLoss><e:ExtraordinaryDividendPaid contextRef="c1047" unitRef="u5" decimals="0">0</e:ExtraordinaryDividendPaid><e:ExtraordinaryDividendPaid contextRef="c1056" unitRef="u5" decimals="0">475000</e:ExtraordinaryDividendPaid><e:Equity contextRef="c139" unitRef="u5" decimals="0">714821</e:Equity><e:Equity contextRef="c500" unitRef="u5" decimals="0">706298</e:Equity><e:Equity contextRef="c140" unitRef="u5" decimals="0">700000</e:Equity><e:Equity contextRef="c501" unitRef="u5" decimals="0">25000</e:Equity><e:DividendPaid contextRef="c141" unitRef="u5" decimals="0">700000</e:DividendPaid><e:DividendPaid contextRef="c502" unitRef="u5" decimals="0">25000</e:DividendPaid><e:Dividend contextRef="c141" unitRef="u5" decimals="0">600000</e:Dividend><e:Dividend contextRef="c502" unitRef="u5" decimals="0">700000</e:Dividend><e:Equity contextRef="c142" unitRef="u5" decimals="0">600000</e:Equity><e:Equity contextRef="c503" unitRef="u5" decimals="0">700000</e:Equity><g:IdentificationOfApprovedAnnualReport contextRef="c1" xml:lang="da">Direktionen har dags dato aflagt årsrapporten for 2023 for PharmAdvice ApS.
</g:IdentificationOfApprovedAnnualReport><g:IdentificationOfApprovedAnnualReport contextRef="c1" xml:lang="en">Today, the Managing Director has approved the annual report of PharmAdvice ApS for the financial year 2023.
</g:IdentificationOfApprovedAnnualReport><g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c1" xml:lang="da">Årsrapporten er aflagt i overensstemmelse med årsregnskabsloven.
</g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c1" xml:lang="en">The annual report has been prepared in accordance with the Danish Financial Statements Act.
</g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c1" xml:lang="da">Jeg anser den valgte regnskabspraksis for hensigtsmæssig, og efter min opfattelse giver årsregnskabet et retvisende billede af selskabets aktiver, passiver og finansielle stilling pr. 31. december 2023 samt af resultatet af selskabets aktiviteter for regnskabsåret 1. januar - 31. december 2023.
</g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c1" xml:lang="en">I consider the chosen accounting policy to be appropriate, and in my opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January – 31 December 2023.
</g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><g:ConfirmationThatFinancialStatementsAreExemptedFromAuditing contextRef="c1" xml:lang="da">Direktionen anser betingelserne for at undlade revision af årsregnskabet for 2023 for opfyldt.
</g:ConfirmationThatFinancialStatementsAreExemptedFromAuditing><g:ConfirmationThatFinancialStatementsAreExemptedFromAuditing contextRef="c1" xml:lang="en">The Managing Director consider the conditions for audit exemption of the 2023 financial statements to be met.
</g:ConfirmationThatFinancialStatementsAreExemptedFromAuditing><g:ManagementsStatementAboutManagementsReview contextRef="c1" xml:lang="da">Ledelsesberetningen indeholder efter min opfattelse en retvisende redegørelse for de forhold, som beretningen omhandler.
</g:ManagementsStatementAboutManagementsReview><g:ManagementsStatementAboutManagementsReview contextRef="c1" xml:lang="en">Further, in my opinion, the Management's review gives a true and fair review of the matters discussed in the Management's review.
</g:ManagementsStatementAboutManagementsReview><g:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c1" xml:lang="da">Årsrapporten indstilles til generalforsamlingens godkendelse.
</g:RecommendationForApprovalOfAnnualReportByGeneralMeeting><g:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c1" xml:lang="en">We recommend that the annual report be approved at the Annual General Meeting.
</g:RecommendationForApprovalOfAnnualReportByGeneralMeeting><d:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c29">Susanne Ølsgaard Felumb</d:NameAndSurnameOfMemberOfExecutiveBoard><f:DescriptionOfOtherEngagement contextRef="c1" xml:lang="da">Vi har opstillet årsregnskabet for PharmAdvice ApS for regnskabsåret 1. januar - 31. december 2023 på grundlag af selskabets bogføring og øvrige oplysninger, som De har tilvejebragt.

Årsregnskabet omfatter anvendt regnskabspraksis, resultatopgørelse, balance, egenkapitalopgørelse og noter.

Vi har udført opgaven i overensstemmelse med ISRS 4410, Opgaver om opstilling af finansielle oplysninger.

Vi har anvendt vores faglige ekspertise til at assistere Dem med at udarbejde og præsentere årsregnskabet i overensstemmelse med årsregnskabsloven. Vi har overholdt relevante bestemmelser i revisorloven og International Ethics Standards Board for Accountants’ internationale retningslinjer for revisorers etiske adfærd (IESBA Code), herunder principper om integritet, objektivitet, professionel kompetence og fornøden omhu.

Årsregnskabet samt nøjagtigheden og fuldstændigheden af de oplysninger, der er anvendt til opstillingen af årsregnskabet, er Deres ansvar.

Da en opgave om opstilling af finansielle oplysninger ikke er en erklæringsopgave med sikkerhed, er vi ikke forpligtet til at verificere nøjagtigheden eller fuldstændigheden af de oplysninger, De har givet os til brug for at opstille årsregnskabet. Vi udtrykker derfor ingen revisions- eller reviewkonklusion om, hvorvidt årsregnskabet er udarbejdet i overensstemmelse med årsregnskabsloven.
</f:DescriptionOfOtherEngagement><f:DescriptionOfOtherEngagement contextRef="c1" xml:lang="en">We have compiled the financial statements of PharmAdvice ApS for the financial year 1 January - 31 December 2023 based on the company's bookkeeping and on information you have provided.

These financial statements comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes.

We performed this compilation engagement in accordance with International Standard on Related Services 4410 (Revised), Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist Management in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements under the Danish Act on Approved Auditors and Audit Firms and International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) including principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these financial statements are prepared in accordance with the Danish Financial Statements Act.
</f:DescriptionOfOtherEngagement><h:DescriptionOfPrimaryActivitiesOfEntity contextRef="c1" xml:lang="da">Selskabets væsentligste aktiviteter
Selskabets formål er at drive virksomhed inden for handel og industri og anden i forbindelse hermed stående virksomhed, primært rådgivning inden for medicinalbranchen.
</h:DescriptionOfPrimaryActivitiesOfEntity><h:DescriptionOfPrimaryActivitiesOfEntity contextRef="c1" xml:lang="en">Description of key activities of the company
the activities are doing business within trade industry and other related business, primarily consulting within the pharmaceutical industry.
</h:DescriptionOfPrimaryActivitiesOfEntity><h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="c1" xml:lang="da">Udvikling i aktiviteter og økonomiske forhold
Årets bruttofortjeneste udgør kr. 5.940.070 mod kr. 5.311.830 sidste år. Det ordinære resultat efter skat udgør kr. 608.525 mod kr. 717.002 sidste år. Ledelsen anser årets resultat for tilfredsstillende.
</h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs><h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="c1" xml:lang="en">Development in activities and financial matters
The gross profit for the year totals DKK 5,940,070  against DKK 5,311,830 last year. Income or loss from ordinary activities after tax totals DKK 780,255 against DKK 717,002 last year. Management considers the net profit or loss for the year satisfactory.
</h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs><h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="c1" xml:lang="da">Begivenheder efter regnskabsårets udløb
Der er efter regnskabsårets udløb ikke indtruffet begivenheder, der væsentligt vil kunne påvirke selskabets finansielle stilling.
</h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod><h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="c1" xml:lang="en">Events occurring after the end of the financial year
After the end of the financial year, no events have occurred that could significantly affect the company's financial position. 
</h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod><e:InformationOnReportingClassOfEntity contextRef="c1" xml:lang="da">Årsrapporten for PharmAdvice ApS er aflagt i overensstemmelse med årsregnskabslovens bestemmelser for en klasse B-virksomhed. Herudover har virksomheden valgt at følge enkelte regler for klasse C-virksomheder.

Årsrapporten er aflagt efter samme regnskabspraksis som sidste år og aflægges i danske kroner.
</e:InformationOnReportingClassOfEntity><e:InformationOnReportingClassOfEntity contextRef="c1" xml:lang="en">The annual report for PharmAdvice ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

The accounting policies are unchanged from last year, and the annual report is presented in DKK.
</e:InformationOnReportingClassOfEntity><e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="c1" xml:lang="da">Generelt om indregning og måling
I resultatopgørelsen indregnes indtægter i takt med, at de indtjenes. Herunder indregnes værdireguleringer af finansielle aktiver og forpligtelser. I resultatopgørelsen indregnes ligeledes alle omkostninger, herunder afskrivninger, nedskrivninger og hensatte forpligtelser samt tilbageførsler som følge af ændrede regnskabsmæssige skøn af beløb, der tidligere har været indregnet i resultatopgørelsen.

Aktiver indregnes i balancen, når det er sandsynligt, at fremtidige økonomiske fordele vil tilflyde selskabet, og aktivets værdi kan måles pålideligt.

Forpligtelser indregnes i balancen, når det er sandsynligt, at fremtidige økonomiske fordele vil fragå selskabet, og forpligtelsens værdi kan måles pålideligt.

Ved første indregning måles aktiver og forpligtelser til kostpris. Efterfølgende måles aktiver og forpligtelser som beskrevet nedenfor for hver enkelt regnskabspost.

Visse finansielle aktiver og forpligtelser måles til amortiseret kostpris, hvorved der indregnes en konstant effektiv rente over løbetiden. Amortiseret kostpris opgøres som oprindelig kostpris med fradrag af eventuelle afdrag samt tillæg/fradrag af den akkumulerede amortisering af forskellen mellem kostpris og nominelt beløb. Herved fordeles kurstab og kursgevinst over aktivets eller forpligtelsens løbetid.

Ved indregning og måling tages hensyn til forudsigelige tab og risici, der fremkommer inden årsrapporten aflægges, og som vedrører forhold, der eksisterede på balancedagen.
</e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies><e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="c1" xml:lang="en">Recognition and measurement in general
Income is recognised in the income statement concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs are recognised in the income statement, including depreciations amortisations, write-downs for impairment, provisions, and reversals due to changes in estimated amounts previously recognised in the income statement.

Assets are recognised in the statement of financial position when it seems probable that future economic benefits will flow to the company and the value of the asset can be reliably measured.

Liabilities are recognised in the statement of financial position when it is seems probable that future economic benefits will flow out of the company and the value of the liability can be reliably measured.

Assets and liabilities are measured at cost at the initial recognition. Hereafter, assets and liabilities are measured as described below for each individual accounting item.

Certain financial assets and liabilities are measured at amortised cost, allowing a constant effective interest rate to be recognised during the useful life of the asset or liability. Amortised cost is recognised as the original cost less any payments, plus/less accrued amortisations of the difference between cost and nominal amount. In this way, capital losses and gains are allocated over the useful life of the liability.

Upon recognition and measurement, allowances are made for such predictable losses and risks which may arise prior to the presentation of the annual report and concern matters that exist on the reporting date.
</e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="c1" xml:lang="da">Bruttofortjeneste
Bruttofortjeneste indeholder nettoomsætning, ændring i lagre af færdigvarer og varer under fremstilling, arbejde udført for egen regning og opført under aktiver, andre driftsindtægter samt eksterne omkostninger.

Nettoomsætning indregnes i resultatopgørelsen, såfremt levering og risikoovergang til køber har fundet sted inden årets udgang, og såfremt indtægten kan opgøres pålideligt og forventes modtaget. Nettoomsætningen måles til dagsværdien af det aftalte vederlag eksklusive moms og afgifter og med fradrag af rabatter i forbindelse med salget.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="c1" xml:lang="en">Gross profit
Gross profit comprises the revenue, changes in inventories of finished goods, and work in progress, own work capitalised, other operating income, and external costs.

Revenue is recognised in the income statement if delivery and passing of risk to the buyer have taken place before the end of the year and if the income can be determined reliably and inflow is anticipated. Revenue is measured at the fair value of the consideration promised exclusive of VAT and taxes and less any discounts relating directly to sales.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="c1" xml:lang="da">Direkte okostninger omfatter omkostninger, der direkte kan tilskrives en bestemt aktivitet.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="c1" xml:lang="en">irect expenses comprises expenses that are directly attributable to a particular activity.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c1" xml:lang="da">Andre eksterne omkostninger omfatter omkostninger til distribution, salg, reklame, administration, lokaler, tab på debitorer mv.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c1" xml:lang="en">Other external expenses comprises expenses incurred for other assistance, related to the income, sales, advertising, administration, premises, loss on receivables, and operational leasing costs, etc.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="c1" xml:lang="da">Personaleomkostninger
Personaleomkostninger omfatter løn og gager, inklusive feriepenge og pensioner samt andre omkostninger til social sikring mv. til selskabets medarbejdere.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="c1" xml:lang="en">Staff costs
Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense><e:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="c1" xml:lang="da">Af- og nedskrivninger
Af- og nedskrivninger indeholder årets af- og nedskrivninger af materielle anlægsaktiver.
</e:DescriptionOfMethodsOfImpairmentLossesAndDepreciation><e:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="c1" xml:lang="en">Depreciation, amortisation, and write-down for impairment
Depreciation, amortisation, and write-down for impairment comprise depreciation on, amortisation of, and write-down for impairment of tangible assets.
</e:DescriptionOfMethodsOfImpairmentLossesAndDepreciation><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="c1" xml:lang="da">Finansielle indtægter og omkostninger
Finansielle indtægter og omkostninger indregnes i resultatopgørelsen med de beløb, der vedrører regnskabsåret. Finansielle poster omfatter renteindtægter og -omkostninger, realiserede og urealiserede kursgevinster og kurstab vedrørende gæld og transaktioner i fremmed valuta, samt tillæg og godtgørelser under acontoskatteordningen mv.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="c1" xml:lang="en">Financial income and expenses
Financial income and expenses are recognised in the income statement with the amounts concerning the financial year. Financial income and expenses comprise interest income and expenses, realised and unrealised capital gains and losses relating to debt and transactions in foreign currency, as well as surcharges and reimbursements under the advance tax scheme, etc.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c1" xml:lang="da">Skat af årets resultat
Årets skat, der består af årets aktuelle selskabsskat og ændring i udskudt skat, indregnes i resultatopgørelsen med den del, der kan henføres til årets resultat, og direkte i egenkapitalen med den del, der kan henføres til posteringer direkte i egenkapitalen. 

Modervirksomheden og de danske tilknyttede virksomheder er omfattet af de danske regler om tvungen sambeskatning af koncernens danske virksomheder.

Den aktuelle danske selskabsskat fordeles ved afregning af sambeskatningsbidrag mellem de sambeskattede virksomheder i forhold til disses skattepligtige indkomster. I tilknytning hertil modtager virksomheder med skattemæssigt underskud sambeskatningsbidrag fra virksomheder, der har kunnet anvende dette underskud (fuld fordeling).
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c1" xml:lang="en">Tax on net profit or loss for the year
Tax for the year comprises the current income tax for the year and changes in deferred tax and is recognised in the income statement with the share attributable to the net profit or loss for the year and directly in equity with the share attributable to entries directly in equity. 

The company is subject to Danish rules on compulsory joint taxation of Danish group enterprises.

The current Danish income tax is allocated among the jointly taxed companies proportional to their respective taxable income (full allocation with reimbursement of tax losses).
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="c1" xml:lang="da">Materielle anlægsaktiver
Materielle anlægsaktiver måles til kostpris med fradrag af akkumulerede afskrivninger og nedskrivninger. 

Afskrivningsgrundlaget er kostpris med fradrag af eventuel forventet restværdi efter afsluttet brugstid. Afskrivningsperioden og restværdien fastsættes på anskaffelsestidspunktet og revurderes årligt. Overstiger restværdien aktivets regnskabsmæssige værdi, ophører afskrivningen.

Der foretages lineære afskrivninger baseret på følgende vurdering af aktivernes forventede brugstider:

Andre anlæg, driftsmateriel og inventar Brugstid 3-5 år
Småaktiver med en forventet levetid under 1 år indregnes i anskaffelsesåret som omkostninger i resultatopgørelsen.

Fortjeneste eller tab ved afhændelse af materielle anlægsaktiver opgøres som forskellen mellem salgspris med fradrag af salgsomkostninger og den regnskabsmæssige værdi på salgstidspunktet. Fortjeneste eller tab indregnes i resultatopgørelsen under andre driftsindtægter eller andre driftsomkostninger.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="c1" xml:lang="en">Property, plant, and equipment
Property, plant, and equipment are measured at cost less accrued depreciation and write-down for impairment. 

The depreciable amount is cost less any expected residual value after the end of the useful life of the asset. The amortisation period and the residual value are determined at the acquisition date and reassessed annually. If the residual value exceeds the carrying amount, the depreciation is discontinued.

Depreciation is done on a straight-line basis according to an assessment of the expected useful life:

Other fixtures and fittings, tools and equipment Useful life 3-5 years
Minor assets with an expected useful life of less than 1 year are recognised as costs in the income statement in the year of acquisition.

Profit or loss derived from the disposal of property, land, and equipment is measured as the difference between the sales price less selling costs and the carrying amount at the date of disposal. Profit or loss is recognised in the income statement as other operating income or other operating expenses.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInvestments contextRef="c1" xml:lang="da">Deposita
Deposita måles til amortiseret kostpris og udgøres af huslejedeposita mv.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInvestments><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInvestments contextRef="c1" xml:lang="en">Deposits
Deposits are measured at amortised cost and represent lease deposits, etc.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInvestments><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="c1" xml:lang="da">Tilgodehavender
Tilgodehavender måles til amortiseret kostpris, hvilket sædvanligvis svarer til nominel værdi.

Nedskrivninger opgøres som forskellen mellem den regnskabsmæssige værdi af tilgodehavender og nutidsværdien af de forventede pengestrømme, herunder realisationsværdi af eventuelle modtagne sikkerhedsstillelser. Som diskonteringssats anvendes den effektive rente for det enkelte tilgodehavende eller portefølje.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="c1" xml:lang="en">Receivables
Receivables are measured at amortised cost, which usually corresponds to nominal value.

Impairment losses are calculated as the difference between the carrying amount of accounts receivable and the present value of the expected cash flows, including the realisable value of any securities received. The effective interest rate for the individual account receivable or portfolio is used as the discount rate.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets contextRef="c1" xml:lang="da">Periodeafgrænsningsposter
Periodeafgrænsningsposter, som er indregnet under aktiver, omfatter afholdte omkostninger vedrørende efterfølgende regnskabsår.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets contextRef="c1" xml:lang="en">Prepayments
Prepayments recognised under assets comprise incurred costs concerning the following financial year.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="c1" xml:lang="da">Likvide beholdninger
Likvide beholdninger omfatter indeståender i pengeinstitutter og kontantbeholdninger.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="c1" xml:lang="en">Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity contextRef="c1" xml:lang="da">Egenkapital</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity contextRef="c1" xml:lang="en">Equity</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity><e:DescriptionOfMethodsOfDividends contextRef="c1" xml:lang="da">Udbytte
Udbytte, som forventes udbetalt for året, vises som en særskilt post under egenkapitalen.
</e:DescriptionOfMethodsOfDividends><e:DescriptionOfMethodsOfDividends contextRef="c1" xml:lang="en">Dividend
Dividend expected to be distributed for the year is recognised as a separate item under equity.
</e:DescriptionOfMethodsOfDividends><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="c1" xml:lang="da">Selskabsskat og udskudt skat
Aktuelle skatteforpligtelser og tilgodehavende aktuel skat indregnes i balancen som beregnet skat af årets skattepligtige indkomst, reguleret for skat af tidligere års skattepligtige indkomster og for betalte acontoskatter.

Selskabet er sambeskattet med koncernforbundne danske selskaber. Den aktuelle selskabsskat fordeles mellem de sambeskattede selskaber i forhold til disses skattepligtige indkomster og med fuld fordeling med refusion vedrørende skattemæssige underskud. De sambeskattede selskaber indgår i acontoskatteordningen.

Skyldige og tilgodehavende sambeskatningsbidrag indregnes i balancen som ”Tilgodehavende skat hos tilknyttede virksomheder" eller ”Skyldig skat hos tilknyttede virksomheder”.

Efter sambeskatningsreglerne hæfter PharmAdvice ApS solidarisk og ubegrænset over for skattemyndighederne for selskabsskatter og kildeskatter på renter, royalties og udbytter opstået inden for sambeskatningskredsen.

Udskudt skat måles efter den balanceorienterede gældsmetode af midlertidige forskelle mellem regnskabsmæssig og skattemæssig værdi af aktiver og forpligtelser opgjort på grundlag af den planlagte anvendelse af aktivet henholdsvis afvikling af forpligtelsen. Udskudt skat måles til nettorealisationsværdi.

Udskudt skat måles på grundlag af de skatteregler og skattesatser i de respektive lande, der med balancedagens lovgivning vil være gældende, når den udskudte skat forventes udløst som aktuel skat. Ændring i udskudt skat som følge af ændringer i skattesatser indregnes i resultatopgørelsen bortset fra poster, der føres direkte på egenkapitalen.

Udskudte skatteaktiver, herunder skatteværdien af fremførselsberettiget skattemæssigt underskud, måles til den værdi, hvortil aktivet forventes at kunne realiseres, enten ved udligning i skat af fremtidig indtjening eller ved modregning i udskudte skatteforpligtelser inden for samme juridiske skatteenhed. Eventuelle udskudte nettoskatteaktiver måles til nettorealisationsværdi.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="c1" xml:lang="en">Income tax and deferred tax
Current tax liabilities and current tax receivable are recognised in the statement of financial position as calculated tax on the taxable income for the year, adjusted for tax of previous years' taxable income and for tax paid on account.

The company is jointly taxed with consolidated Danish companies. The current corporate income tax is distributed between the jointly taxed companies in proportion to their taxable income and with full distribution with reimbursement as to tax losses. The jointly taxed companies are comprised by the Danish tax prepayment scheme.

Joint taxation contributions payable and receivable are recognised in the statement of financial position as ”Tax receivables from group enterprises" or "Income tax payable to group enterprises"

According to the rules of joint taxation, PharmAdvice ApS is unlimitedly, jointly, and severally liable to pay the Danish tax authorities the total income tax, including withholding tax on interest, royalties, and dividends, arising from the jointly taxed group of companies.

Deferred tax is measured on the basis of temporary differences in assets and liabilities with a focus on the statement of financial position. Deferred tax is measured at net realisable value.

Deferred tax is measured based on the tax rules and tax rates applying under the legislation prevailing in the respective countries on the reporting date when the deferred tax is expected to be released as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement, except for items included directly in the equity.

Deferred tax assets, including the tax value of tax losses allowed for carryforward, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit. Any deferred net tax assets are measured at net realisable value.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c1" xml:lang="da">Gældsforpligtelser
Øvrige gældsforpligtelser, som omfatter gæld til leverandører, tilknyttede virksomheder samt anden gæld, måles til amortiseret kostpris, hvilket sædvanligvis svarer til nominel værdi.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c1" xml:lang="en">Liabilities other than provisions
Other liabilities concerning payables to suppliers, group enterprises, and other payables are measured at amortised cost which usually corresponds to the nominal value.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><e:DisclosureOfContingentLiabilities contextRef="c1" xml:lang="da">3. Eventualposter
Contingencies
Eventualforpligtelser
Contingent liabilities
Lejeforpligtelse, uopsigelighedsperiode på 4 måneder, kr. 102.000.
Rental obligation, non-cancellation period, 4. months, DKK. 102.000.

Sambeskatning
Joint taxation
Selskabet indgår i den nationale sambeskatning med Felumb Holding ApS, CVR-nr. 36 91 59 43, som er administrationsselskab og hæfter ubegrænset og solidarisk med de øvrige sambeskattede selskaber for den samlede selskabsskat.
With Felumb Holding ApS, company reg. no 36 91 59 43 as administration company, the company is subject to the Danish scheme of joint taxation and unlimitedly, jointly, and severally liable, along with the other jointly taxed companies, for the total corporation tax.

</e:DisclosureOfContingentLiabilities><!--Aktuelle periode enkelt selskab--><context id="c1"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period></context><!--Forrige periode enkelt selskab--><context id="c2"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period></context><!--Slutdato forrige periode enkelt selskab--><context id="c3"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2022-12-31</instant></period></context><!--Slutdato aktuelle periode enkelt selskab--><context id="c4"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2023-12-31</instant></period></context><!--CEO1--><context id="c29"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfExecutiveBoardDimension"><d:memberOfBoardIdentifier>1</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--REVISOR1--><context id="c37"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfAuditorDimension"><d:auditorIdentifier>1</d:auditorIdentifier></xbrldi:typedMember></scenario></context><!--Virksomhedskapital aktuel primo--><context id="c119"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel ultimo--><context id="c121"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel primo--><context id="c137"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel i aaret--><context id="c138"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel ultimo--><context id="c139"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Udbytte aktuel primo--><context id="c140"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Udbytte aktuel i aaret--><context id="c141"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Udbytte aktuel ultimo--><context id="c142"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital forrige EKprimo--><context id="c478"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2022-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital forrige EKultimo--><context id="c480"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2022-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKprimo--><context id="c498"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2022-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKi aaret--><context id="c499"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKultimo--><context id="c500"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2022-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Udbytte forrige EKprimo--><context id="c501"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2022-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Udbytte forrige EKi aaret--><context id="c502"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Udbytte forrige EKultimo--><context id="c503"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><instant>2022-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Ekstraordinart udbytte aktuel i aaret--><context id="c1047"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedExtraordinaryDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Ekstraordinart udbytte forrige EKi aaret--><context id="c1056"><entity><identifier scheme="http://www.dcca.dk/cvr">26527651</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedExtraordinaryDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--DKK enere--><unit id="u5"><measure>iso4217:DKK</measure></unit><!--Antal--><unit id="u7"><measure>xbrli:pure</measure></unit></xbrl>
